Targeted therapy for cholangiocarcinoma
Mené sur 73 patients atteints d’un cholangiocarcinome de stade avancé avec mutation du gène IDH, cet essai multicentrique de phase I évalue la dose maximale tolérée et la toxicité limitant la dose d'un traitement par ivosidenib
Progress in the identification of effective treatment for patients with advanced biliary tract cancers has been slow. By necessity (due to the relative infrequency of these malignancies), clinical studies of advanced disease have pooled patients with cholangiocarcinoma (intrahepatic, perihilar, and distal subtypes according to anatomical origin), gallbladder cancer, and (sometimes) ampullary cancers.
The Lancet Gastroenterology & Hepatology , commentaire, 2018